Zoledronic acid + Placebo

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Complex Regional Pain Syndromes

Conditions

Complex Regional Pain Syndromes

Trial Timeline

Dec 1, 2013 → Dec 1, 2016

NCT ID

NCT01788176

About Zoledronic acid + Placebo

Zoledronic acid + Placebo is a phase 2 stage product being developed by Novartis for Complex Regional Pain Syndromes. The current trial status is unknown. This product is registered under clinical trial identifier NCT01788176. Target conditions include Complex Regional Pain Syndromes.

What happened to similar drugs?

7 of 19 similar drugs in Complex Regional Pain Syndromes were approved

Approved (7) Terminated (4) Active (10)

✅clarithromycin, rifabutinPfizerApproved

✅Pregabalin + PregabalinPfizerApproved

✅AzithromycinPfizerApproved

✅Azithromycin + Rifabutin/rifampinPfizerApproved

✅vigabatrinLundbeckApproved

✅SabrilLundbeckApproved

✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01788176	Phase 2	UNKNOWN	Dec 1, 2013	Dec 1, 2016	Complex Regional Pain Syndromes
NCT01702415	Approved	Withdrawn	Oct 1, 2013	Dec 1, 2015	Cystic Fibrosis
NCT01166178	Phase 3	Terminated	Oct 1, 2010	Jun 1, 2012	Osteoporosis
NCT00844480	Phase 2	Terminated	Mar 1, 2010	Jan 1, 2016	Bone Loss
NCT01016093	Phase 2/3	UNKNOWN	Nov 1, 2009	Dec 1, 2011	Beta-Thalassemia
NCT00781261	Phase 2	UNKNOWN	Aug 1, 2009	Dec 1, 2013	Osteonecrosis
NCT00799266	Phase 3	Completed	Dec 4, 2008	Mar 5, 2018	Osteoporosis
NCT00333229	Approved	Terminated	Mar 1, 2006	Dec 1, 2013	Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
NCT00320710	Phase 3	Completed	Feb 1, 2006	Jul 1, 2013	Breast Cancer
NCT00375505	Phase 3	Completed	Oct 1, 2005	May 1, 2014	Breast Cancer
NCT00145327	Phase 3	Completed	May 1, 2005	Nov 1, 2009	Osteoporosis
NCT00132808	Phase 3	Completed	Jul 1, 2004	Feb 1, 2008	Osteopenia

Competing Products

20 competing products in Complex Regional Pain Syndromes

See all competitors

Product	Company	Stage	Hype Score
Zonisamide	Eisai	Phase 3	40
Eslicarbazepine acetate + Eslicarbazepine acetate	Sumitomo Pharma	Phase 3	40
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	40
RAD001 + Placebo	Novartis	Phase 2	35
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	40
everolimus	Novartis	Phase 3	44
ranolazine	Gilead Sciences	Phase 2	35
clarithromycin, rifabutin	Pfizer	Approved	43
Pregabalin + Pregabalin	Pfizer	Approved	35
Pregabalin	Pfizer	Pre-clinical	18
Azithromycin	Pfizer	Approved	43
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	43
Stavudine	Bristol Myers Squibb	Phase 3	40
Zidovudine + Didanosine	Bristol Myers Squibb	Phase 2	35
Haemocomplettan® P + Human albumin (Placebo)	CSL	Phase 2/3	38
BE1116 + FFP	CSL	Phase 3	47
CSL730 + Placebo	CSL	Phase 1	21
vigabatrin	Lundbeck	Approved	32
Sabril	Lundbeck	Approved	40
GWP42003-P	Jazz Pharmaceuticals	Phase 3	29